News stories about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive on Monday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Albany Molecular Research earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4611922429328 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Albany Molecular Research (NASDAQ:AMRI) opened at $21.74 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.68 and a quick ratio of 0.37. Albany Molecular Research has a 12 month low of $13.01 and a 12 month high of $22.17.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Albany Molecular Research (AMRI) Share Price” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/12/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-albany-molecular-research-amri-share-price.html.
Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
Receive News & Ratings for Albany Molecular Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research and related companies with MarketBeat.com's FREE daily email newsletter.